CTLA4 and cancer: Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1), anti-programmed cell death ligand-1 (PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4), have revolutionized the treatment of cancer in the past decades.